Company Overview and News

 
Prospect Awards review: Grange upgrades Savage River mill to drive efficiencies

2017-11-22 australianmining.com.au
Metso engineered services product manager – Australian market area John Aran, Grange Resources senior engineering manager Frank Lovell and Vega Australia business development manager NSW Tony Scarborough
Upvote Downvote

 
'Backs against the wall': Calls for government to buy Tasmanian Gas Pipeline

2017-11-12 abc.net.au
One of Tasmania's biggest employers wants the State Government to invest hundreds of millions of dollars to buy a key piece of energy infrastructure — the undersea gas pipeline.
Upvote Downvote

 
All the winners from the 2017 Prospect Awards

2017-10-27 australianmining.com.au
The Moranbah North team from Anglo American with their Australian Mine of the Year award. Photo by: photographicmemory.com.au
Upvote Downvote

6
Use Your Extraordinary Edge With These 2 Investment Strategies

2017-10-18 seekingalpha
Researchers find returns of between 20 and 30% for net-nets. James Montier published similar returns for international stocks ranked on 5 value criteria. I will describe these results below.
Upvote Downvote

 
Clark to lead Kasbah

2017-09-26 businessnews.com.au
Tin explorer Kasbah Resources has recruited former Wolf Minerals boss Russell Clark as its new chief executive.
Upvote Downvote

 
Grange Resources: A Mining Net-Net Stock With A 8% Yield

2017-06-16 seekingalpha
Net-Net: AUD 157 million net cash with a capitalization of AUD 162 million and 8% dividend.
Upvote Downvote

 
Small miners under big pressure if iron ore price falls

2017-04-05 abc.net.au
Surging iron ore prices over the past six months and the lower Australian dollar have extended the stay of execution for many of Australia's smaller iron ore miners.
Upvote Downvote

 
Gas price hike fears for Tasmania's big industry

2017-03-21 abc.net.au
Tasmania's major industrials could be hit by a perfect storm of price hikes when a gas contract is finalised between Hydro and the owners of the gas pipeline.
Upvote Downvote

 
Grange Resources shares in pre-open

2017-03-19 proactiveinvestors.com.au
Grange Resources (ASX:GRR) has been granted a trading halt by the ASX, with its shares placed in pre-open.
Upvote Downvote

 
Day traders? Taxi drivers? Making sense of the surge in iron ore prices

2017-02-14 smh.com.au
So who is setting the iron ore price, could it be day traders in China, or is it taxi drivers in Dalian, as some analysts suspect?
Upvote Downvote

 
Day traders? Taxi drivers? Making sense of the surge in iron ore prices

2017-02-14 theage.com.au
So who is setting the iron ore price, could it be day traders in China, or is it taxi drivers in Dalian, as some analysts suspect?
Upvote Downvote

 
Mid-size miners on the rebound after hitting bottom: PwC

2016-11-22 abc.net.au
A new report says the mining industry has passed the worst of the downturn and is making a comeback boosted by gold and lithium miners.
Upvote Downvote

 
Grange Resources posts $80m loss after iron ore prices dip lower

2016-07-07 abc.net.au
The Tasmanian Opposition is alarmed by a sharp drop in mineral exploration, as the state's biggest iron ore miner posts an $80 million loss for the six months to July.
Upvote Downvote

 
Results of Meeting

2016-05-11 asx.com.au
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...